Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Blood|March 3, 2007
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSuzanne Trudel, Zhi Hua Li, Jennifer Rauw, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 9, 2023
The Impact of CD34<sup>+</sup> Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple MyelomaEyal Lebel, Katherine Lajkosz, Esther Masih-Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Leukemia & Lymphoma|January 10, 2015
Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplantVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 7, 2019
Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center ExperienceMajed Alahmadi, Esther Masih-Khan, Eshetu G Atenafu, et al.
Leukemia & Lymphoma|December 21, 2013
Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survivalVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
Blood|December 16, 2004
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myelomaSuzanne Trudel, Zhi Hua Li, Ellen Wei, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Blood|April 3, 2010
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myelomaJames W Clendening, Aleksandra Pandyra, Zhihua Li, et al.
British Journal of Haematology|February 12, 2004
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myelomaJoshua L Paterson, Zhihua Li, Xiao-Yan Wen, et al.
Pageof 11